Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Trial Evaluating αDC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies

Next Previous
Trial Profile

A Phase 1/2 Trial Evaluating αDC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Dendritic cell vaccines (Primary) ; Interferon alpha-2b (Primary) ; Rintatolimod (Primary)
  • Indications Adenocarcinoma; Appendiceal cancer; Carcinoma; Colon cancer; Colorectal cancer; Mesothelioma; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 09 Jul 2021 Status changed from no longer recruiting to discontinued as per results published in the Annals of Surgical Oncology
  • 09 Jul 2021 Results (N=46) of an evaluable data analysis published in the Annals of Surgical Oncology
  • 26 Dec 2018 Planned End Date changed from 1 Dec 2018 to 18 Feb 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top